Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to the creation of innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas.
For more information, please visit the company’s website at http://www.ono.co.jp/eng/index.html.
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious diseases, Oncology, Neuroscience and Diabetes Mellitus (DM) Complications and Kidney diseases.
For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.
Haplogen is a privately held biopharmaceutical company based in Vienna, Austria, with the mission to improve human health by combating viral infections and other diseases. For these efforts, Haplogen employs a proprietary functional genomics platform based on haploid genetics in human cell lines to identify host factors. Haplogen was founded in 2010 as a spin-out of CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences.
For more information on Haplogen visit: www.haplogen.com.
Hospital for Sick Children
The Hospital for Sick Children (SickKids), affiliated with the University of Toronto, is Canada's most research-intensive hospital and the largest centre dedicated to improving children's health in the country. As innovators in child health, SickKids improves the health of children by integrating care, research and teaching. With a staff that includes professionals from all disciplines of health care and research, SickKids provides the best in complex and specialized care by creating scientific and clinical advancements, sharing knowledge and expertise and championing the development of an accessible, comprehensive and sustainable child health system.
More information is available at: www.sickkids.ca.
German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ)
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.
For more information on the DKFZ, see: www.dkfz.de/en/.
Fundación MEDINA is a non-profit research organisation established in Granada, Spain, from the private-public partnership between the Government of Andalucía, the University of Granada and Merck Sharp and Dohme de España S.A. Fundación MEDINA owns one of the largest and most chemically diverse microbial natural product libraries of extracts with a long track record of success in delivering novel drug candidates in the pharmaceutical sector. Fundación MEDINA has a unique expertise in natural products microbiology, chemistry and high throughput screening, and is developing drug discovery programs in infectious diseases (including tuberculosis and parasitic diseases), oncology, and rare diseases. Fundación MEDINA is establishing contract research collaborations and partnerships with pharma and biotech companies to discover novel therapeutics.
For additional information visit: www.medinadiscovery.com
McGill University/Goodman Cancer Research Centre
Cyclenium has entered into multiple research agreements with McGill University involving investigators from the Rosalind and Morris Goodman Cancer Research Centre (GCRC), the Departments of Biochemistry and Physiology, and the McGill High Throughput Screening (HTS) facility. Founded in Montreal, Quebec, in 1821, McGill is a leading Canadian post-secondary institution. It has two campuses, 11 faculties, 11 professional schools, 300 programs of study and some 39,000 students, including more than 9,300 graduate students. McGill attracts students from over 150 countries around the world, its 8,200 international students making up 21 per cent of the student body. Almost half of McGill students claim a first language other than English, including approximately 40 per cent whose first language is French or who speak it fluently.
More information on McGill University is available at www.mcgill.ca.
Additional information on the GCRC is available at www.mcgillgcrc.com.
For more information on the McGill Life Science Complex HTS Facility, please see: https://www.mcgill.ca/lifesciencescomplex/core/hts-hcs
Institute for Research in Immunology and Cancer — Commercialization of Research
The Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) is a not-for-profit drug discovery and commercialization centre based at the Institute for Research in Immunology and Cancer (IRIC, http://www.iric.ca) of the Université de Montréal (UdeM). IRIC is an ultra-modern research hub and training centre located in the heart of the UdeM created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer.
IRICoR’s main objective is to rapidly translate highly innovative scientific projects from IRIC, UdeM and various centres into high value novel therapies in oncology, immunology and related indications through strong partnerships with the private sector — thereby efficiently bridging the innovation translation gap between early stage academic research and industry.
For more information see: http://www.iricor.ca
Southern Research Institute
Southern Research Institute is a not-for-profit 501(c)(3) scientific research organization founded in 1941 and headquartered in Birmingham, AL, that conducts preclinical drug discovery and development, advanced engineering research in materials, systems development, and environment and energy research. From discovery to clinical trials, Southern Research contributes to the search for new and better drugs and vaccines through a comprehensive continuum of capabilities and support services.
This collaboration is utilizing Cyclenium’s proprietary libraries of next generation macrocyclic molecules and associated hit-to-lead optimization expertise in combination with Southern Research’s extensive capabilities in target screening, compound profiling and preclinical development to discover and jointly develop new clinical candidates for the treatment of cancer, infectious diseases and neurological conditions.
For more information visit: http://www.southernresearch.org
The NEOMED Institute, established in 2012, is a not‐for‐profit organization whose mission is to bridge the gap between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with the creation of a vibrant and sustainable life science ecosystem. NEOMED operates two fully integrated research and development campuses in Montreal: one specializing in small molecule therapeutics, and the other specializing in the development of biologics and vaccines. Both facilities function as open‐access drug discovery hubs housing independent commercial businesses (30 independent companies employing more than 300 people) and providing a dynamic environment that stimulates collaboration, innovation, and creativity. NEOMED’s wholly-owned for-profit subsidiary, NEOMED-LABS, a Contract Research Organization (CRO) providing customized and high-throughput immune-monitoring for clinical vaccine development, is one of these tenants. NEOMED is jointly funded by our pharmaceutical partners, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada.
For additional information on NEOMED and the NEOMED Institute see: http://www.neomed.ca
TransBIOTech is an applied research center located in Lévis, Québec. Its mission is to support innovation by giving companies access to state-of-the-art biotechnological expertise in the life sciences. In synergy with its partners, TransBIOTech is committed to utilizing the expertise of its research professionals in order to rapidly support and accomplish project goals in accordance with internationally-recognized quality standards. The center mainly provides R&D services and technical assistance to enterprises. TransBIOTech assists their partners at various stages of development of their innovations, both in terms of product characterization and preclinical studies. TransBIOTech also offers its clients a unique approach based on dynamic customer-oriented flexibility, synergy, collaboration, commitment to quality and a flexible approach to managing intellectual property.
Through an NSERC-Applied Research and Development (ARD) grant, TransBIOTech and Cyclenium, have initiated a collaboration that aims to assess the pharmacokinetic parameters of selected novel macrocycles from Cyclenium's compound collection.
For more information about TransBIOTech’s expertise and services, please visit: www.tbt.qc.ca
University of Sherbrooke
Cyclenium is collaborating with the innovative research group of Professor Yves Dory at the Institute of Pharmacology and the Department of Chemistry, University of Sherbrooke, on the discovery and optimization of macrocyclic δ-opioid receptor agonists as new treatments for chronic pain. Professor Dory is the recipient of an NSERC-Collaborative Research and Development (CRD) grant for support of this project.